How I Treat How I treat infant leukemia
暂无分享,去创建一个
[1] R. Stam,et al. Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo , 2018, Haematologica.
[2] R. Stam,et al. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis , 2018, Leukemia.
[3] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[4] S. Raimondi,et al. Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group , 2017 .
[5] E. Mejstrikova,et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment , 2017, Blood Cancer Journal.
[6] R. Pieters,et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol , 2017, Leukemia.
[7] S. Raimondi,et al. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. , 2017, Blood.
[8] M. Absalon,et al. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03) , 2017, Pediatric blood & cancer.
[9] E. Clappier,et al. The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.
[10] Adrian J. Thrasher,et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.
[11] Heather L. Mulder,et al. Pediatric non–Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes , 2017, Nature Genetics.
[12] M. Valsecchi,et al. Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis , 2016, Scientific Reports.
[13] A. Borkhardt,et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Stam,et al. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations , 2016, Oncotarget.
[15] T. Lassmann,et al. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin , 2016, Leukemia.
[16] R. Mcmasters,et al. Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy , 2016, Pediatric blood & cancer.
[17] D. Maloney,et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.
[18] H. Dombret,et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. , 2016, The Lancet. Haematology.
[19] R. Stam,et al. Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities , 2016, Haematologica.
[20] R. Scharpf,et al. Identifying Subclonal Epigenetic Changes Driving Chemoresistance in Infant MLL-r Acute Lymphoblastic Leukemias , 2015 .
[21] M. Loh,et al. Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition , 2015 .
[22] E. Sison,et al. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL , 2015, Oncotarget.
[23] R. Stam,et al. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia. , 2015, European journal of cancer.
[24] R. Marschalek,et al. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)‐rearranged infant acute lymphoblastic leukaemia , 2015, British journal of haematology.
[25] I. Pastan,et al. Characterization of CD22 expression in acute lymphoblastic leukemia , 2015, Pediatric blood & cancer.
[26] Cheng Cheng,et al. The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias , 2015, Nature Genetics.
[27] M. Loh,et al. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group , 2015, Pediatric blood & cancer.
[28] S. Armstrong,et al. The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia , 2014 .
[29] M. Sulis,et al. Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium , 2014 .
[30] D. Small,et al. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition , 2014, Oncotarget.
[31] E. Sison,et al. Does hematopoietic stem cell transplantation benefit infants with acute leukemia? , 2013, Hematology. American Society of Hematology. Education Program.
[32] T. Druley,et al. Excess congenital non-synonymous variation in leukemia-associated genes in MLL− infant leukemia: a Children's Oncology Group report , 2013, Leukemia.
[33] R. Pieters,et al. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements , 2013, Leukemia.
[34] R. Houlston,et al. The silent mutational landscape of infant MLL‐AF4 pro‐B acute lymphoblastic leukemia , 2013, Genes, chromosomes & cancer.
[35] Robert A Copeland,et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.
[36] E. Sison,et al. Dynamic Chemotherapy-Induced Upregulation of CXCR4 Expression: A Mechanism of Therapeutic Resistance in Pediatric AML , 2013, Molecular Cancer Research.
[37] R. Stam,et al. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants , 2013, Haematologica.
[38] S. Armstrong,et al. Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l , 2013, Leukemia.
[39] S. Armstrong,et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. , 2013, Blood.
[40] D. Small,et al. MLL‐rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism , 2013, British journal of haematology.
[41] M. Eguchi,et al. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements , 2013, Leukemia.
[42] N. Heerema,et al. Genetic variants modify susceptibility to leukemia in infants: A Children's Oncology Group report , 2013, Pediatric blood & cancer.
[43] M. González-Díaz,et al. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia , 2012, Leukemia.
[44] W. Carroll,et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. , 2012, Blood.
[45] Xiaomin Lu,et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] R. Stam,et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia , 2012, Leukemia.
[47] D. Reinhardt,et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report , 2012, Leukemia.
[48] K. Wheatley,et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial , 2011, British journal of haematology.
[49] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[50] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[51] Lars Bullinger,et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.
[52] Yonghong Xiao,et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.
[53] Yi Zhang,et al. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. , 2011, Blood.
[54] R. Pieters,et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale , 2011, Leukemia.
[55] R. Irizarry,et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. , 2010, Blood.
[56] E. van den Berg,et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] R. Stam,et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. , 2010, Blood.
[58] M. Relling,et al. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol , 2010, Pediatric blood & cancer.
[59] R. Stam,et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. , 2009, Blood.
[60] K. Koh,et al. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan infant leukemia study group , 2009, Pediatric blood & cancer.
[61] Cheng Cheng,et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.
[62] R. Pieters,et al. Pharmacokinetics of high‐dose methotrexate in infants treated for acute lymphoblastic leukemia , 2009, Pediatric blood & cancer.
[63] M. D. Boer,et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol , 2009 .
[64] R. Stam,et al. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. , 2007, Blood.
[65] M. Eguchi,et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group , 2007, Leukemia.
[66] R. Pieters,et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.
[67] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[68] N. Heerema,et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. , 2006, Blood.
[69] M. Levis,et al. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner , 2006, Leukemia.
[70] M. D. Boer,et al. The MLL recombinome of acute leukemias , 2006, Leukemia.
[71] S. Armstrong,et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.
[72] G. Gustafsson,et al. Cellular drug sensitivity in MLL‐rearranged childhood acute leukaemia is correlated to partner genes and cell lineage , 2005, British journal of haematology.
[73] J. Potter,et al. Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group , 2005, Cancer Epidemiology Biomarkers & Prevention.
[74] N. Goulden,et al. Characterization of acute lymphoblastic leukemia progenitor cells. , 2004, Blood.
[75] M. D. Boer,et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype , 2004, Leukemia.
[76] Y. Hayashi,et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. , 2003, Blood.
[77] S. Armstrong,et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. , 2003, Blood.
[78] Rob Pieters,et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.
[79] P. Nowell,et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. , 2002, Blood.
[80] R. Pieters,et al. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. , 2002, Blood.
[81] M. Greaves,et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. , 2001, Cancer research.
[82] J. Rowley,et al. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[83] M. Greaves,et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[84] G. Basso,et al. The role of immunophenotype in acute lymphoblastic leukemia of infant age. , 1994, Leukemia & lymphoma.
[85] M. Greaves,et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias , 1993, Nature.
[86] R. Stam,et al. Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia. , 2013, European journal of cancer.
[87] A. Biondi,et al. Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients , 2011, Leukemia.
[88] R. Arceci. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study , 2010 .
[89] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[90] A. Zipursky,et al. Origins of leukaemia in children with Down syndrome , 2005, Nature Reviews Cancer.
[91] L. J,et al. Rearrangement of the MLL Gene Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia , Regardless of Presenting Age , 2002 .
[92] E. Lander,et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.
[93] L. Silverman,et al. Clinical Trials and Observations , 2022 .